Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.
J Clin OncolJul 24, 2026 (epub)
Clinical ResearchOncology (Medical)
Yuanyuan Zhao, Hongyun Zhao, Qiming Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase Ib multicenter study evaluated the efficacy and safety of izalontamab brengitecan (iza-bren) in patients with extensive-stage small cell lung cancer (ES-SCLC) who had progressed on prior therapies. The objective response rate (ORR) was 48.1%, with a median progression-free survival (PFS) of 4.1 months and median overall survival (OS) of 12.2 months.
Key findings
- The ORR for all patients was 48.1% (95% CI, 34.0 to 62.4).
- In second-line treatment, the ORR was 72.7% (95% CI, 49.8 to 89.3).
- Median PFS was 6.2 months (95% CI, 3.7 to 8.2) for second-line patients.
- The most common treatment-related adverse events were hematologic toxicities.
Why it matters
The study highlights a potential new treatment option for patients with relapsed extensive-stage small cell lung cancer, an area with limited effective therapies. The promising response rates, especially in the second-line setting, warrant further investigation.